Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Not yet recruiting

• Conditions: Micropulse Laser; Central Serous Chorioretinopathy; Photodynamic Therapy

• Registration Number: NCT06468540
• Lead Sponsor: Beijing Hospital

Brief Summary

In this study, patients with chronic central serous chorioretinopathy who were treated by micropulse laser alone or micropulse laser combined with photodynamic therapy without drugs are retrospectively included. The visual acuity changes, subretinal fluid absorption and choroidal characteristics of the two groups are compared 1 to 6 months after treatment. We will also analyze baseline characteristics that influence post-treatment outcomes to identify potential predictors of poor treatment outcomes.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-06
• Study First Submitted: 2024-06-08
• Study Start: 2024-06-15
• Study First Submitted QC: 2024-06-15
• Last Update Submitted: 2024-06-15
• Study First Posted: 2024-06-21
• Last Update Posted: 2024-06-21
• Primary Completion: 2025-06-15
• Study Completion: 2025-12-15

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Age >18 years old.
• The patient diagnosed with chronic central serous chorioretinopathy with a history of more than 6 months. The diagnostic criteria for chronic CSC were as follows: FFA examination showed leakage of strong fluorescent spots with the extension of angiography time, and late fluorescence accumulation, accompanied by decreased central vision, darkening of vision, and deformable microopia. Fundus examination showed superficial detachment of retinal neuroepithelium in macula.
• Patients received single micropulse laser therapy or micropulse laser combined with drug-free photodynamic therapy, and had not received other laser or surgical treatment in the six months prior to treatment.
• Patients had follow-up data before and after treatment for 1 month and at least 6 months.

Exclusion Criteria

• Patients with other fundus diseases or refractive interstitial opacity.
• During treatment, other treatments other than micropulse laser or drug-free photodynamic therapy were received.
• Various reasons led to incomplete patient data.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
BCVA	1 month and 6 months	Best-corrected visual acuity using logMAR
CRT	1 month and 6 months	Central retinal thickness on OCT

Secondary Outcome Measures

Name	Time	Method
SFCT	1 month and 6 months	subfoveal choroidal thickness on OCTA